Combination of acalabrutinib with lenalidomide and rituximab in relapsed/refractory aggressive B-cell non-Hodgkin lymphoma: a single-arm phase II trial

被引：6

作者：

Park, Changhee ^{[1
]}

Lee, Ho Sup ^{[2
]}

Kang, Ka-Won ^{[3
]}

Lee, Won-Sik ^{[4
]}

Do, Young Rok ^{[5
]}

Kwak, Jae-Yong ^{[6
]}

Shin, Ho-Jin ^{[7
]}

Kim, Sung-Yong ^{[8
]}

Yi, Jun Ho ^{[9
]}

Lim, Sung-Nam ^{[10
]}

Lee, Jeong-Ok ^{[11
]}

Yang, Deok-Hwan ^{[12
]}

Jang, Hun ^{[13
]}

Choi, Byoungsan ^{[13
]}

Lim, Jiwoo ^{[14
]}

Sun, Choong Hyun ^{[14
]}

Byun, Ja Min ^{[1
]}

Yoon, Sung-Soo ^{[1
]}

Koh, Youngil ^{[1
,14
]}

机构：

[1] Seoul Natl Univ Hosp, Dept Internal Med, Seoul, South Korea

[2] Kosin Univ, Coll Med, Gospel Hosp, Dept Internal Med, Pusan, South Korea

[3] Korea Univ, Coll Med, Anam Hosp, Dept Internal Med, Seoul, South Korea

[4] Busan Paik Hosp, Dept Internal Med, Pusan, South Korea

[5] Keimyung Univ, Dongsan Med Ctr, Dept Internal Med, Daegu, South Korea

[6] Jeonbuk Natl Univ, Med Sch, Dept Internal Med, Jeonju, South Korea

[7] Pusan Natl Univ, Sch Med, Dept Internal Med, Pusan, South Korea

[8] KonKuk Univ, KonKuk Univ Hosp, Dept Internal Med, Dept Hematol Oncol, Seoul, South Korea

[9] Chung Ang Univ, Dept Internal Med, Dept Med, Div Hematol Oncol, Seoul, South Korea

[10] Inje Univ, Dept Internal Med, Dept Hematol Oncol, Haeundae Paik Hosp, Pusan, South Korea

[11] Seoul Natl Univ, Bundang Hosp, Dept Internal Med, Seongnam, South Korea

[12] Chonnam Natl Univ, Hwasun Hosp, Dept Internal Med, Hwasun, South Korea

[13] PROTEINA Co Ltd, Dept Biomarker Discovery, Seoul, South Korea

[14] GenomeOpinion Inc, Seoul, South Korea

来源：

NATURE COMMUNICATIONS | 2024年 / 15卷 / 01期

关键词：

BRUTON TYROSINE KINASE; ELDERLY-PATIENTS; IBRUTINIB; INHIBITOR; ACTIVATION; EXPRESSION; CHOP; TOOL;

D O I：

10.1038/s41467-024-47198-4

中图分类号：

O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];

学科分类号：

07 ; 0710 ; 09 ;

摘要：

Potential synergism between Bruton's tyrosine kinase (BTK) inhibitor and lenalidomide in treating aggressive B-cell lymphoma has been suggested. Here, the authors report a single-arm phase II clinical trial of combination of acalabrutinib, lenalidomide and rituximab (R2A) in patients with aggressive relapsed/refractory aggressive (R/R) B-cell non-Hodgkin lymphoma (NHL). The primary endpoint of this study is objective response rate (ORR), and the secondary endpoints are complete remission (CR) rate, duration of response (DoR), progression-free survival (PFS) and overall survival (OS). A total of 66 patients are enrolled mostly with diffuse large B-cell lymphoma. The ORR is 54.5% and CR rate is 31.8% meeting the primary end point. The median DoR is 12.9 months, and 1-year PFS and OS rate is 33.1% and 67.5% respectively. Adverse events (AE) are manageable with the most frequent AE being neutropenia (31.8%). Patients with MYD88 mutations, subtypes known for NF-kappa B activation, and high BTK expression by immunohistochemistry respond well. Overall, these results show a significant efficacy of the R2A regimen in patients with aggressive R/R B-cell NHL, with exploratory biomarkers suggesting potential associations with response. (ClinicalTrials.gov 51 identifier: NCT04094142) Potential synergism between BTK inhibitor and lenalidomide in treating aggressive B-cell lymphoma has been suggested. Here, the authors report a single-arm phase II clinical trial of combination of acalabrutinib, lenalidomide and rituximab in patients with aggressive Relapsed/Refractory aggressive B-cell non-Hodgkin lymphoma.

引用

页数：11

共 39 条

[1] Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study [J].

Abramson, Jeremy S. ;

Palomba, M. Lia ;

Gordon, Leo I. ;

Lunning, Matthew A. ;

Wang, Michael ;

Arnason, Jon ;

Mehta, Amitkumar ;

Purev, Enkhtsetseg ;

Maloney, David G. ;

Andreadis, Charalambos ;

Sehgal, Alison ;

Solomon, Scott R. ;

Ghosh, Nilanjan ;

Albertson, Tina M. ;

Garcia, Jacob ;

Kostic, Ana ;

Mallaney, Mary ;

Ogasawara, Ken ;

Newhall, Kathryn ;

Kim, Yeonhee ;

Li, Daniel ;

Siddiqi, Tanya .

LANCET, 2020, 396 (10254) :839-852

[2]

[Anonymous], 2017, Common Terminology Criteria for Adverse Events (CTCAE) Common Terminology Criteria for Adverse Events (CTCAE) v5.0

[3] Acalabrutinib (ACP-196): A Covalent Bruton Tyrosine Kinase Inhibitor with a Differentiated Selectivity and In Vivo Potency Profile [J].

Barf, Tjeerd ;

Covey, Todd ;

Izumi, Raquel ;

van de Kar, Bas ;

Gulrajani, Michael ;

van Lith, Bart ;

van Hoek, Maaike ;

de Zwart, Edwin ;

Mittag, Diana ;

Demont, Dennis ;

Verkaik, Saskia ;

Krantz, Fanny ;

Pearson, Paul G. ;

Ulrich, Roger ;

Kaptein, Allard .

JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2017, 363 (02) :240-252

[4]

Benjamin DI, 2019, bioRxiv, DOI [10.1101/861054, 10.1101/861054, DOI 10.1101/861054]

[5] Practical issues in CAR T-cell therapy [J].

Byun, Ja Min .

BLOOD RESEARCH, 2023, 58 :11-12

[6] Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes [J].

Chapuy, Bjoern ;

Stewart, Chip ;

Dunford, Andrew J. ;

Kim, Jaegil ;

Kamburov, Atanas ;

Redd, Robert A. ;

Lawrence, Mike S. ;

Roemer, Margaretha G. M. ;

Li, Amy J. ;

Ziepert, Marita ;

Staiger, Annette M. ;

Wala, Jeremiah A. ;

Ducar, Matthew D. ;

Leshchiner, Ignaty ;

Rheinbay, Ester ;

Taylor-Weiner, Amaro ;

Coughlin, Caroline A. ;

Hess, Julian M. ;

Pedamallu, Chandra S. ;

Livitz, Dimitri ;

Rosebrock, Daniel ;

Rosenberg, Mara ;

Tracy, Adam A. ;

Horn, Heike ;

van Hummelen, Paul ;

Feldman, Andrew L. ;

Link, Brian K. ;

Novak, Anne J. ;

Cerhan, James R. ;

Habermann, Thomas M. ;

Siebert, Reiner ;

Rosenwald, Andreas ;

Thorner, Aaron R. ;

Meyerson, Matthew L. ;

Golub, Todd R. ;

Beroukhim, Rameen ;

Wulf, Gerald G. ;

Ott, German ;

Rodig, Scott J. ;

Monti, Stefano ;

Neuberg, Donna S. ;

Loeffler, Markus ;

Pfreundschuh, Michael ;

Truemper, Lorenz ;

Getz, Gad ;

Shipp, Margaret A. .

NATURE MEDICINE, 2018, 24 (05) :679-+

[7] Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification [J].

Cheson, Bruce D. ;

Fisher, Richard I. ;

Barrington, Sally F. ;

Cavalli, Franco ;

Schwartz, Lawrence H. ;

Zucca, Emanuele ;

Lister, T. Andrew .

JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (27) :3059-+

[8]

Cliff Edward R Scheffer, 2023, Am Soc Clin Oncol Educ Book, V43, pe397912, DOI 10.1200/EDBK_397912

[9] CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. [J].

Coiffier, B ;

Lepage, E ;

Brière, J ;

Herbrecht, R ;

Tilly, H ;

Bouabdallah, R ;

Morel, P ;

Van den Neste, E ;

Salles, G ;

Gaulard, P ;

Reyes, F ;

Gisselbrecht, C .

NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (04) :235-242

[10]

Dotan Efrat, 2010, P T, V35, P148

← 1 2 3 4 →